Publication: Pathway Analyses Implicate Glial Cells in Schizophrenia
Open/View Files
Date
2014
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Public Library of Science
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Duncan, Laramie E., Peter A. Holmans, Phil H. Lee, Colm T. O'Dushlaine, Andrew W. Kirby, Jordan W. Smoller, Dost Öngür, and Bruce M. Cohen. 2014. “Pathway Analyses Implicate Glial Cells in Schizophrenia.” PLoS ONE 9 (2): e89441. doi:10.1371/journal.pone.0089441. http://dx.doi.org/10.1371/journal.pone.0089441.
Research Data
Abstract
Background: The quest to understand the neurobiology of schizophrenia and bipolar disorder is ongoing with multiple lines of evidence indicating abnormalities of glia, mitochondria, and glutamate in both disorders. Despite high heritability estimates of 81% for schizophrenia and 75% for bipolar disorder, compelling links between findings from neurobiological studies, and findings from large-scale genetic analyses, are only beginning to emerge. Method Ten publically available gene sets (pathways) related to glia, mitochondria, and glutamate were tested for association to schizophrenia and bipolar disorder using MAGENTA as the primary analysis method. To determine the robustness of associations, secondary analyses were performed with: ALIGATOR, INRICH, and Set Screen. Data from the Psychiatric Genomics Consortium (PGC) were used for all analyses. There were 1,068,286 SNP-level p-values for schizophrenia (9,394 cases/12,462 controls), and 2,088,878 SNP-level p-values for bipolar disorder (7,481 cases/9,250 controls). Results: The Glia-Oligodendrocyte pathway was associated with schizophrenia, after correction for multiple tests, according to primary analysis (MAGENTA p = 0.0005, 75% requirement for individual gene significance) and also achieved nominal levels of significance with INRICH (p = 0.0057) and ALIGATOR (p = 0.022). For bipolar disorder, Set Screen yielded nominally and method-wide significant associations to all three glial pathways, with strongest association to the Glia-Astrocyte pathway (p = 0.002). Conclusions: Consistent with findings of white matter abnormalities in schizophrenia by other methods of study, the Glia-Oligodendrocyte pathway was associated with schizophrenia in our genomic study. These findings suggest that the abnormalities of myelination observed in schizophrenia are at least in part due to inherited factors, contrasted with the alternative of purely environmental causes (e.g. medication effects or lifestyle). While not the primary purpose of our study, our results also highlight the consequential nature of alternative choices regarding pathway analysis, in that results varied somewhat across methods, despite application to identical datasets and pathways.
Description
Other Available Sources
Keywords
Biology, Genetics, Human genetics, Genetic association studies, Genome-wide association studies, Mitochondrial diseases, Genetics of disease, Neuroscience, Neurochemistry, Neurochemicals, Glutamate, Medicine, Mental health, Psychiatry, Mood disorders, Psychoses, Schizophrenia, Social and behavioral sciences, Psychology, Clinical psychology
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service